A dose-ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity

Authors

  • Nathalie Andreu,

    1. Laboratoire de Pharmacologie Médicale et Clinique and Service de Pharmacologie Cliniqe, INSERM U 317, Faculté de Médecine, Toulouse, France
    Search for more papers by this author
  • Christine Damase-Michel,

    1. Laboratoire de Pharmacologie Médicale et Clinique and Service de Pharmacologie Cliniqe, INSERM U 317, Faculté de Médecine, Toulouse, France
    Search for more papers by this author
  • Jean-Michel Senard,

    1. Laboratoire de Pharmacologie Médicale et Clinique and Service de Pharmacologie Cliniqe, INSERM U 317, Faculté de Médecine, Toulouse, France
    Search for more papers by this author
  • Olivier Rascol,

    1. Laboratoire de Pharmacologie Médicale et Clinique and Service de Pharmacologie Cliniqe, INSERM U 317, Faculté de Médecine, Toulouse, France
    Search for more papers by this author
  • Prof. Jean-Louis Montastruc

    Corresponding author
    1. Laboratoire de Pharmacologie Médicale et Clinique and Service de Pharmacologie Cliniqe, INSERM U 317, Faculté de Médecine, Toulouse, France
    • Laboratoire de Pharmacologie Médicale et Clinique, Inserm U 317, Faculté de Médecine, 37 allées Jules-Guesde, 31073 Toulouse Cedex, France
    Search for more papers by this author

Abstract

A dose-ranging study of selegiline was performed in patients with Parkinson's disease to determine the minimal dosage of the drug able to inhibit ≥95% of platelet monoamine oxidase (MAO) activity. Different doses of selegiline (5 or 10 mg daily, 10 or 20 mg weekly) were studied in four groups of six patients with Parkinson's disease. Platelet MAO activity was measured before and after 1 month's treatment with selegiline. The doses of 5 or 10 mg daily and 20 mg (i.e., 10 mg × 2) weekly induced a complete inhibition of platelet MAO-B activity from day 7 to day 28 (96.0–99.5%). In contrast, platelet MAO-B inhibition was only 75.9% of the basal value after a dosage of 10 mg weekly. These results demonstrate that 20 mg weekly is the minimal dosage of selegiline able to induce a maximal and long-lasting inhibition of platelet MAO-B activity in patients with parkinsonism. Further clinical trials are needed to investigate the clinical efficacy of this dose.

Ancillary